Acadia Pharmaceuticals Share Price Today
(NASDAQ: ACAD)

Name: Acadia Pharmaceuticals Share Price Today (NASDAQ: ACAD) - Acadia Pharmaceuticals Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Acadia Pharmaceuticals share price is $17.19 & ₹1,499.10 as on 12 Mar 2025, 2.30 'hrs' IST

$17.19

Market is closed - opens 7 PM, 12 Mar 2025

View live Acadia Pharmaceuticals share price in Dollar and Rupees. Guide to invest in Acadia Pharmaceuticals stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Acadia Pharmaceuticals, along with analyst recommendations, forecasts, and comprehensive financials.

Acadia Pharmaceuticals share price movements

Today's Low: $16.87
Today's High: $17.44
$17.19
1.89%
Downside
Day's Volatility :3.27%
Upside
1.41%
52 Weeks Low: $14.15
52 Weeks High: $24.27
$17.19
17.68%
Downside
52 Weeks Volatility :41.7%
Upside
29.17%

Acadia Pharmaceuticals (ACAD) Returns

Period	Acadia Pharmaceuticals Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	-4.61%	3.9%	0.0%
6 Months	7.77%	-4.9%	0.0%
1 Year	-13.96%	0.9%	0.0%
3 Years	-22.81%	14.5%	-10.6%

Acadia Pharmaceuticals (ACAD) Key Statistics

in dollars & INR

Previous Close	$17.19
Open	$17.1
Today's High	$17.435
Today's Low	$16.865
Market Capitalization	$2.9B
Today's Volume	$1.8M
52 Week High	$24.27
52 Week Low	$14.15
Revenue TTM	$957.8M
EBITDA	$100.2M
Earnings Per Share (EPS)	$1.33
PE Ratio	12.92
Profit Margin	23.64%
Quarterly Earnings Growth YOY	2.13%
Return On Equity TTM	38.89%

How to invest in Acadia Pharmaceuticals Stock (ACAD) from India?

It is very easy for Indian residents to invest directly in Acadia Pharmaceuticals from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Acadia Pharmaceuticals stock in both Indian Rupees (INR) and US Dollars (USD). Search for Acadia Pharmaceuticals or ACAD on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Acadia Pharmaceuticals or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Acadia Pharmaceuticals shares which would translate to 0.051 fractional shares of Acadia Pharmaceuticals as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Acadia Pharmaceuticals, in just a few clicks!

Returns in Acadia Pharmaceuticals (ACAD) for Indian investors in Rupees

The Acadia Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Acadia Pharmaceuticals investment value today

Current value as on today

₹91,436

Returns

₹8,564

(-8.56%)

Returns from Acadia Pharmaceuticals Stock

₹13,964 (-13.96%)

Dollar Returns

₹5,400 (+5.4%)

Indian investors sentiment towards Acadia Pharmaceuticals (ACAD)

-50%

Period: Feb 9, 2025 to Mar 11, 2025. Change in 30 Days versus previous period

Search interest for Acadia Pharmaceuticals Stock from India on INDmoney has decreased by -50% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Acadia Pharmaceuticals

Baker Bros Advisors LP
25.71%
Vanguard Group Inc
8.36%
BlackRock Inc
7.63%
RTW INVESTMENTS, LLC
5.22%
Morgan Stanley - Brokerage Accounts
4.38%
State Street Corp
2.71%

Analyst Recommendation on Acadia Pharmaceuticals

Buy

73%Buy

23%Hold

3%Sell

Based on 26 Wall street analysts offering stock ratings for Acadia Pharmaceuticals(by analysts ranked 0 to 5 stars)

Based on 26 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Acadia Pharmaceuticals Stock (ACAD)

What analysts predicted

Upside of 44.56%

Target:

$24.85

Current:

$17.19

Insights on Acadia Pharmaceuticals Stock (Ticker Symbol: ACAD)

Price Movement
In the last 7 days, ACAD stock has moved down by -5.9%
Increasing Revenue
Revenue is up for the last 4 quarters, 205.83M → 259.60M (in $), with an average increase of 7.3% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, 32.76M → 143.74M (in $), with an average increase of 77.2% per quarter
ACAD vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 56.3% return, outperforming this stock by 85.1%
ACAD vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 50.4% return, outperforming this stock by 76.2%
Price to Sales
ForACAD every $1 of sales, investors are willing to pay $3.0, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $13.6 for every $1 of sales.

ACAD Acadia Pharmaceuticals Financials in INR & Dollars

	FY19	Y/Y Change
Revenue	$339.1M	↑ 51.5%
Net Income	$-235.3M	↓ 4.05%
Net Profit Margin	-69.38%	↑ 40.18%

	FY20	Y/Y Change
Revenue	$441.8M	↑ 30.28%
Net Income	$-281.6M	↑ 19.69%
Net Profit Margin	-63.74%	↑ 5.64%

	FY21	Y/Y Change
Revenue	$484.1M	↑ 9.6%
Net Income	$-167.9M	↓ 40.38%
Net Profit Margin	-34.67%	↑ 29.07%

	FY22	Y/Y Change
Revenue	$517.2M	↑ 6.83%
Net Income	$-216.0M	↑ 28.66%
Net Profit Margin	-41.76%	↓ 7.09%

	FY23	Y/Y Change
Revenue	$726.4M	↑ 40.45%
Net Income	$-61.3M	↓ 71.62%
Net Profit Margin	-8.44%	↑ 33.32%

	FY24	Y/Y Change
Revenue	$957.8M	↑ 31.85%
Net Income	$226.5M	↓ 469.5%
Net Profit Margin	23.64%	↑ 32.08%

	Q3 FY23	Q/Q Change
Revenue	$211.7M	↑ 28.12%
Net Income	$-65.2M	↓ 5950.63%
Net Profit Margin	-30.79%	↓ 31.46%

	Q4 FY23	Q/Q Change
Revenue	$231.0M	↑ 9.14%
Net Income	$45.8M	↓ 170.27%
Net Profit Margin	19.82%	↑ 50.61%

	Q1 FY24	Q/Q Change
Revenue	$205.8M	↓ 10.91%
Net Income	$16.6M	↓ 63.85%
Net Profit Margin	8.04%	↓ 11.78%

	Q2 FY24	Q/Q Change
Revenue	$242.0M	↑ 17.55%
Net Income	$33.4M	↑ 101.69%
Net Profit Margin	13.8%	↑ 5.76%

	Q3 FY24	Q/Q Change
Revenue	$250.4M	↑ 3.49%
Net Income	$32.8M	↓ 1.87%
Net Profit Margin	13.09%	↓ 0.71%

	Q4 FY24	Q/Q Change
Revenue	$259.6M	↑ 3.67%
Net Income	$143.7M	↑ 338.71%
Net Profit Margin	55.37%	↑ 42.28%

	FY19	Y/Y Change
Profit	$319.5M	↑ 55.48%

	FY20	Y/Y Change
Profit	$421.2M	↑ 31.84%

	FY21	Y/Y Change
Profit	$465.0M	↑ 10.4%

	FY22	Y/Y Change
Profit	$507.1M	↑ 9.05%

	FY23	Y/Y Change
Profit	$680.7M	↑ 34.24%

	FY24	Y/Y Change
Profit	$876.0M	↑ 28.68%

	Q3 FY23	Q/Q Change
Profit	$197.1M	↑ 24.91%

	Q4 FY23	Q/Q Change
Profit	$213.2M	↑ 8.16%

	Q1 FY24	Q/Q Change
Profit	$182.9M	↓ 14.2%

	Q2 FY24	Q/Q Change
Profit	$223.7M	↑ 22.34%

	Q3 FY24	Q/Q Change
Profit	$231.5M	↑ 3.49%

	Q4 FY24	Q/Q Change
Profit	$237.8M	↑ 2.7%

	FY19	Y/Y Change
Operating Cash Flow	$-151.1M	↓ 9.76%
Investing Cash Flow	$-165.8M	↑ 131.97%
Financing Cash Flow	$371.8M	↑ 21.26%

	FY20	Y/Y Change
Operating Cash Flow	$-136.2M	↓ 9.9%
Investing Cash Flow	$192.5M	↓ 216.08%
Financing Cash Flow	$81.0M	↓ 78.22%

	FY21	Y/Y Change
Operating Cash Flow	$-125.7M	↓ 7.72%
Investing Cash Flow	$-71.1M	↓ 136.93%
Financing Cash Flow	$18.2M	↓ 77.58%

	FY22	Y/Y Change
Operating Cash Flow	$-114.0M	↓ 9.25%
Investing Cash Flow	$73.2M	↓ 203.01%
Financing Cash Flow	$8.2M	↓ 54.86%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$-59.0M	↓ 818.88%
Investing Cash Flow	$34.1M	↓ 117.56%
Financing Cash Flow	$12.8M	↑ 132.77%

Acadia Pharmaceuticals Technicals Summary

Sell

Neutral

Buy

Acadia Pharmaceuticals is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Acadia Pharmaceuticals (ACAD) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Acadia Pharmaceuticals Inc.	-8.95%	7.77%	-13.96%	-22.81%	-51.75%
Regeneron Pharmaceuticals, Inc.	7.89%	-34.75%	-23.26%	13.47%	59.99%
Beone Medicines Ltd	10.47%	14.92%	48.19%	65.38%	67.81%
Vertex Pharmaceuticals Incorporated	6.39%	5.32%	21.23%	106.89%	126.39%
Alnylam Pharmaceuticals, Inc.	-14.96%	-11.01%	58.93%	53.54%	129.47%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Acadia Pharmaceuticals Inc.	12.92	12.92	-0.42	0.57	0.39	0.05	NA	4.4
Regeneron Pharmaceuticals, Inc.	18.45	18.45	1.04	42.83	0.16	0.07	0.01	273.57
Beone Medicines Ltd	NA	NA	NA	1.43	-0.19	-0.06	NA	31.22
Vertex Pharmaceuticals Incorporated	32.84	NA	1.35	18.06	-0.03	0.13	NA	63.87
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	0.57	-15.01	-0.03	NA	0.52

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Acadia Pharmaceuticals Inc.	Buy	$2.9B	-51.75%	12.92	23.64%
Regeneron Pharmaceuticals, Inc.	Buy	$77.3B	59.99%	18.45	31.07%
Beone Medicines Ltd	NA	$28.7B	67.81%	NA	-16.92%
Vertex Pharmaceuticals Incorporated	Buy	$125.4B	126.39%	32.84	-4.86%
Alnylam Pharmaceuticals, Inc.	Buy	$31.7B	129.47%	NA	-12.37%

About Acadia Pharmaceuticals

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin which completed Phase III study to treat the negative symptoms of schizophrenia; ACP-101 which completed phase III study for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 that completed phase II study for the treatment of Alzheimer's disease psychosis and Lewy Body Dementia with psychosis; ACP-711 which is in phase I study for the treatment of essential tremor; ACP-211 which is in phase I study for the treatment of treatment-resistant depression; ACP-2591that is in Phase I development for Rett syndrome and Fragile X syndrome; and ACP-271, a GPR88 agonist used in evaluation of neurology and is in the IND-enabling stage. The company has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Organization	Acadia Pharmaceuticals
Employees	653
CEO	Ms. Catherine E. Owen Adams
Industry	Health Technology

Management People of Acadia Pharmaceuticals

Name	Title
Mr. Mark C. Schneyer	Executive VP & CFO
Mr. Stephen R. Davis J.D.	Consultant
Ms. Catherine E. Owen Adams	CEO & Director
Dr. Elizabeth H.Z. Thompson Ph.D.	Head of Research & Development
Mr. Benir Ruano	Senior Vice President of Technical Development, Operations & Quality
Mr. Albert S. Kildani	Senior Vice President of Investor Relations & Corporate Communications
Ms. Jennifer J. Rhodes J.D.	Chief Legal Officer & Secretary
Mr. Rob Ackles	Chief People Officer
Mr. Bob Mischler	Senior Vice President of New Product Planning & Strategy
Ms. Ponni Subbiah M.D., M.P.H.	SVP, Global Head of Medical Affairs & Chief Medical Officer

Important FAQs about investing in ACAD Stock from India :

What is Acadia Pharmaceuticals share price today?

Acadia Pharmaceuticals share price today stands at $17.19, Open: $17.10 ; Previous Close: $17.19 ; High: $17.44 ; Low: $16.87 ; 52 Week High: $24.27 ; 52 Week Low: $14.15.

The stock opens at $17.10, after a previous close of $17.19. The stock reached a daily high of $17.44 and a low of $16.87, with a 52-week high of $24.27 and a 52-week low of $14.15.

Can Indians buy Acadia Pharmaceuticals shares?

Yes, Indians can invest in the Acadia Pharmaceuticals (ACAD) from India.

With INDmoney, you can buy Acadia Pharmaceuticals at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Acadia Pharmaceuticals at zero transaction cost.

How can I buy Acadia Pharmaceuticals shares from India?

It is very easy to buy Acadia Pharmaceuticals from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Acadia Pharmaceuticals (ACAD) be purchased?

Yes, you can buy fractional shares of Acadia Pharmaceuticals with INDmoney app.

What are the documents required to start investing in Acadia Pharmaceuticals stocks?

To start investing in Acadia Pharmaceuticals, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.